A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease

Neurol Sci. 2020 Aug;41(8):2267-2270. doi: 10.1007/s10072-020-04377-7. Epub 2020 Apr 28.

Abstract

EPM2A has been certified as a causative gene in patients with Lafora disease (LD), which is a rare autosomal recessive and severe form of progressive myoclonus epilepsy. LD classically starts in adolescence, characterized by various types of seizure with myoclonic seizure as the main type. Typically within 10 years, intractable seizure attack, rapidly progressing dementia, and a vegetative state were present. LD is particularly frequently found in Mediterranean countries. Here, we report a Chinese family with a novel compound heterozygous mutation in the EPM2A gene, characterized by recurrent vomiting, intractable epilepsy, and progressive cognitive decline.

Keywords: Chinese family; EPM2A; Heterozygous mutation; Lafora disease; Progressive myoclonic epilepsy.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • China
  • Humans
  • Lafora Disease* / genetics
  • Male
  • Mutation / genetics
  • Protein Tyrosine Phosphatases, Non-Receptor / genetics
  • Seizures
  • Ubiquitin-Protein Ligases

Substances

  • Ubiquitin-Protein Ligases
  • Protein Tyrosine Phosphatases, Non-Receptor
  • EPM2A protein, human